Results 91 to 100 of about 8,937,523 (396)

Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001

Annals of Oncology, 2019
Background In the ongoing phase I PROFILE 1001 study, crizotinib showed antitumor activity in patients with ROS1-rearranged advanced non-small-cell lung cancer (NSCLC).
A. Shaw, Gregory Riely, Y. Bang, D. Kim, D. Camidge, B. Solomon, M. Varella-Garcia, A. Iafrate, G. Shapiro, T. Usari, S. C. Wang, K. Wilner, J. Clark, S. Ou   +13 more
semanticscholar   +1 more source

Functional connectivity within glioblastoma impacts overall survival

Neuro-Oncology, 2020
Background Glioblastoma (GBM; World Health Organization grade IV) assumes a variable appearance on MRI owing to heterogeneous proliferation and infiltration of its cells.
A. Daniel, K. Park, J. Roland, D. Dierker, J. Gross, Joseph B. Humphries, C. Hacker, A. Snyder, J. Shimony, E. Leuthardt   +9 more
semanticscholar   +1 more source

The cytoskeletal control of B cell receptor and integrin signaling in normal B cells and chronic lymphocytic leukemia

FEBS Letters, EarlyView.
In lymphoid organs, antigen recognition and B cell receptor signaling rely on integrins and the cytoskeleton. Integrins act as mechanoreceptors, couple B cell receptor activation to cytoskeletal remodeling, and support immune synapse formation as well as antigen extraction.
Abhishek Pethe, Tanja Nicole Hartmann
wiley   +1 more source

Nomograms to predict overall survival and cancer-specific survival in patients with adrenocortical carcinoma

Cancer Management and Research, 2018
Yan Li,1 Xiaohui Bian,2 Junyu Ouyang,2 Shuyi Wei,2 Meizhi He,2 Zelong Luo1 1Department of Oncology, Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China; 2The Second School of Clinical Medicine, Southern Medical University ...
Li Y, Bian XH, Ouyang JY, Wei SY, He MZ, Luo ZL   +5 more
doaj  

Nomograms for Predicting Overall Survival Among Patients with Craniopharyngiomas at Initial Diagnosis: A SEER Population-Based Analysis

International Journal of General Medicine, 2021
Haibo Teng,1,* Zhiyong Liu,1,* Ouying Yan,2 Wenbo He,1 Danyang Jie,3 Yuanwei Qie,4 Jianguo Xu1 1Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu, People’s Republic of China; 2The Affiliated Cancer Hospital of Xiangya ...
Teng H, Liu Z, Yan O, He W, Jie D, Qie Y, Xu J   +6 more
doaj  

Progression‐free survival as a surrogate marker of overall survival [PDF]

Cancer, 2011
The use of progression‐free survival as a surrogate marker of efficacy in cancer treatment has been the subject of much discussion in recent years. However, it should not be considered a surrogate marker for overall survival.
openaire   +3 more sources

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

New England Journal of Medicine, 2018
BACKGROUND The cyclin‐dependent kinase 4 and 6 (CDK4/6) inhibitor palbociclib, in combination with fulvestrant therapy, prolongs progression‐free survival among patients with hormone‐receptor–positive, human epidermal growth factor receptor 2 (HER2 ...
N. Turner, D. Slamon, J. Ro, I. Bondarenko, S. Im, N. Masuda, M. Colleoni, A. DeMichele, S. Loi, S. Verma, H. Iwata, N. Harbeck, S. Loibl, F. André, K. Theall, Xin Huang, C. Giorgetti, C. H. Bartlett, M. Cristofanilli   +18 more
semanticscholar   +1 more source

B cell mechanobiology in health and disease: emerging techniques and insights into therapeutic responses

FEBS Letters, EarlyView.
B cells sense external mechanical forces and convert them into biochemical signals through mechanotransduction. Understanding how malignant B cells respond to physical stimuli represents a groundbreaking area of research. This review examines the key mechano‐related molecules and pathways in B lymphocytes, highlights the most relevant techniques to ...
Marta Sampietro, Marco Cellani, Cristina Scielzo   +2 more
wiley   +1 more source

Adjuvant therapy for early uterine high-grade leiomyosarcoma [PDF]

, 2019
TO THE EDITOR: The article by Hensley et al1 recently published in Journal of Clinical Oncology was interesting, even if apparently negative (Gynecology Oncology Group [GOG]-0277 randomized phase III trial). The study investigated the activity and safety
Panici, P. B., Tomao, F., Tomao, S.
core   +1 more source

The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2

JAMA Oncology, 2019
Key Points Question Does treatment with abemaciclib plus fulvestrant prolong the overall survival (OS) of patients with hormone receptor (HR)–positive, ERBB2 (formerly HER2)-negative advanced breast cancer who progressed during prior endocrine therapy ...
G. Sledge, M. Toi, P. Neven, J. Sohn, Kenichi Inoue, X. Pivot, O. Burdaeva, M. Okera, N. Masuda, P. Kaufman, H. Koh, E. Grischke, P. Conte, Yi Lu, S. Barriga, K. Hurt, Martin Frenzel, S. Johnston, A. Llombart-Cussac   +18 more
semanticscholar   +1 more source